1)Ishihara S, Horiguchi A, Miyakawa S, et al:Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pncreat Sci 23:149-157, 2016
2)日本肝癌研究会:第18回全国原発性肝癌追跡調査報告.日本肝癌研究会事務局,2009
3)Valle J, Wasan H, Palmer DH, et al:ABC-02 Trial Investigators:Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281, 2010
4)Okusaka T, Nakachi K, Fukutomi A, et al:Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer:a comparative multicentre study in Japan. Br J Cancer 103:469-474, 2010
5)Kato A, Shimizu H, Ohtsuka M, et al:Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer:A retrospective single center study. Ann Surg Oncol 20:318-324, 2013
6)Kato A, Shimizu H, Ohtsuka M, et al:Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery. Ann Surg Oncol 22:1093-1099, 2015
7)Folprecht G, Grothey A, Alberts S, et al:Neoadjuvant treatment of unresectable colorectal liver metastases:correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
8)Bismuth H, Adam R, Levi F, et al:Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522, 1996
9)Alberts SR, Horvath WL, Sternfeld WC, et al:Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer:a North Central Cancer Treatment Group phase Ⅱ study. J Clin Oncol 23:9243-9249, 2005
10)Nuzzo G, Giuliante F, Ardito F, et al:Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 11:318-324, 2007
11)日本肝胆膵外科学会(編):臨床・病理 胆道癌取扱い規約 第6版.金原出版,2013
12)Katz MH, Fleming JB, Bhosale P, et al:Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118:5749-5756, 2012
13)Eisenhauer EA, Therasse P, Bogaerts J, et al:New response evaluation criteria in solidtumours:revised RECIST guideline(version 1.1). Eur J Cancer 45:228-247, 2009
14)Katz MH, Varadhachary GR, Fleming JB, et al:Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17:1749-1801, 2010
15)Lee JY, Kim HJ, Yim SH, et al:Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer. Korean J Gastroenterol 62:227-233, 2013
16)Lee SW, Kim HJ, Park JH, et al:Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 45:560-566, 2010